Gilead Sciences, Inc. - GILD - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

Gilead Sciences, Inc. - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
GILD	Nasdaq	8731	http://www.gilead.com/	51.94 +0.91
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Gilead Sciences, Inc. Final Glance: Biotechnology companies - Jun 18th, 2013 4:01 pm Final Glance: Biotechnology companies - Jun 18th, 2013 4:01 pm Midday Glance: Biotechnology companies - Jun 18th, 2013 11:17 am Midday Glance: Biotechnology companies - Jun 18th, 2013 11:17 am The Best Healthcare Bet - Jun 18th, 2013 10:34 am An Interview With Elemer Piros: A Strong Year For Biotechs, Looking From The Halfway Point - Jun 18th, 2013 9:34 am Early Glance: Biotechnology companies - Jun 18th, 2013 8:21 am Early Glance: Biotechnology companies - Jun 18th, 2013 8:21 am Today’s 3 Worst Stocks - Jun 17th, 2013 5:08 pm Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard - Jun 17th, 2013 3:01 pm Gilead Sciences to Present at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18 - Jun 17th, 2013 2:30 pm Huge Upside on Pipeline Strength - Jun 17th, 2013 8:47 am Gilead's Potential Megablockbuster Raises the Bar - Jun 17th, 2013 6:17 am InPlay: Gilead Sciences reports interim Phase 2 data for Idelalisib showing response in refractory indolent non-hodgkin's lymphoma - Jun 17th, 2013 2:54 am Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin’s Lymphoma - Jun 17th, 2013 2:00 am 3 Key Advances in HIV Prevention - Jun 15th, 2013 6:01 am Stanley Druckenmiller's new stock picks - Jun 14th, 2013 10:47 am Consider Biotech Gilead Sciences Because Of Atripla, Sofosbuvir And Great R&D - Jun 14th, 2013 5:41 am Biotech Stock Mailbag: Exact Sciences, Questcor, Biotech M&A, Celsion - Jun 14th, 2013 5:00 am [video] SCOTUS: Human Genes Can't Be Patented - Jun 13th, 2013 5:10 pm View All Current Headlines >>